(Q38462629)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947084%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

title

PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947084%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947084%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Mattheos Bobos

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947084%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Dimosthenis Miliaras

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947084%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

H P Kalofonos

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947084%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

4

Anna Batistatou

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947084%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

author name string

Georgia Karayannopoulou

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947084%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Georgia Gourgioti

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947084%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Ioannis Efstratiou

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947084%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Eleni Galani

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947084%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

George Pentheroudakis

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947084%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Dimitrios Pectasides

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947084%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Gerasimos Aravantinos

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947084%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Dimitrios Bafaloukos

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947084%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Pavlos Papakostas

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947084%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Evangelia Razis

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947084%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Kalliopi Petraki

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947084%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Maria Sotiropoulou

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947084%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Konstantine T Kalogeras

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947084%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

George Fountzilas

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947084%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

publication date

7 May 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947084%20AND%20SRC:MED&resulttype=core&format=json

Cancer Chemotherapy and Pharmacology

7 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947084%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

volume

75

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947084%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947084%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

page(s)

1289-1301

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947084%20AND%20SRC:MED&resulttype=core&format=json

HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial

7 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2762-3

Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2762-3

Protumorigenic activity of plasminogen activator inhibitor-1 through an antiapoptotic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2762-3

Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2762-3

Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2762-3

External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2762-3

Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2762-3

Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2762-3

Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2762-3

Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III tri

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2762-3

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2762-3

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2762-3

Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2762-3

Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2762-3

Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2762-3

HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2762-3

Tissue microarray technology for high-throughput molecular profiling of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2762-3

Type-1 plasminogen activator inhibitor in human breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2762-3

Comparison of immunohistochemistry with immunoassay (ELISA) for the detection of components of the plasminogen activation system in human tumour tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2762-3

Optimized immunohistochemistry in combination with image analysis: a reliable alternative to quantitative ELISA determination of uPA and PAI-1 for routine risk group discrimination in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2762-3

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2762-3

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2762-3

uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2762-3

Real-time quantitative PCR determination of urokinase-type plasminogen activator receptor (uPAR) expression of isolated micrometastatic cells from bone marrow of breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2762-3

Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC alpha and Src inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2762-3

RNAi-mediated downregulation of uPAR synergizes with targeting of HER2 through the ERK pathway in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2762-3